Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant prevention study in adults with migraine and inadequate response to oral preventive medications
2024-513270-21-00Phase 4Completed
- Sponsor
- Pfizer
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 4, randomised, double-blind trial in migraine comparing Rimegepant with Placebo (2 arms). Primary endpoint: Mean change in monthly migraine days over the entire double-blind treatment phase. Started Mar 2023; status: completed.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on 2024-513270-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513270-21-00.